{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:41:42Z","timestamp":1782924102752,"version":"3.54.5"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T00:00:00Z","timestamp":1601856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40121-020-00350-1","type":"journal-article","created":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T05:04:27Z","timestamp":1601874267000},"page":"757-767","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections"],"prefix":"10.1007","volume":"9","author":[{"given":"Tanaya","family":"Bhowmick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin P.","family":"Weinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"350_CR1","doi-asserted-by":"crossref","unstructured":"Lai CC, Chen CC, Tang HJ. Meropenem-vaborbactam in the treatment of acute bacterial infections. J Clin Med.\u00a02019;8(10):1650.","DOI":"10.3390\/jcm8101650"},{"issue":"4","key":"350_CR2","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1128\/AAC.00826-13","volume":"58","author":"SM Drawz","year":"2014","unstructured":"Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors: a therapeutic renaissance in an MDR world. Antimicrob Agents Chemother. 2014;58(4):1835\u201346.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR3","unstructured":"Letourneau A. Combination beta-lactamase inhibitors, carbapenems, and monobactams. In: Hooper D, Bloom A (Ed.) UpToDate, Waltham, MA. 2020."},{"issue":"Suppl 1","key":"350_CR4","doi-asserted-by":"publisher","first-page":"10A","DOI":"10.1177\/14732300020300S103","volume":"30","author":"D Adam","year":"2002","unstructured":"Adam D. Beta-lactam\/beta-lactamase inhibitor combinations in empiric management of pediatric infections. J Int Med Res. 2002;30(Suppl 1):10A\u2013A1919.","journal-title":"J Int Med Res"},{"key":"350_CR5","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S0924-8579(99)00086-2","volume":"12","author":"S Finegold","year":"1999","unstructured":"Finegold S. In vitro efficacy of betalactam\/beta-lactamase inhibitor combinations against bacteria involved in mixed infections. Int J Antimicrob Agents. 1999;12:S9\u2013S14.","journal-title":"Int J Antimicrob Agents"},{"issue":"12","key":"350_CR6","first-page":"e01426","volume":"63","author":"M Biagi","year":"2019","unstructured":"Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E. Exploring aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam as potential treatments for metallo- and serine-\u03b2-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(12):e01426\u2013e1519.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR7","doi-asserted-by":"crossref","unstructured":"Shields RK, Clancy CJ, Hao B, et al. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Antimicrob Agents Chemother. 2015;59(9):5793\u20137.","DOI":"10.1128\/AAC.00548-15"},{"issue":"12","key":"350_CR8","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/ciw636","volume":"63","author":"RK Shields","year":"2016","unstructured":"Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime\u2013avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae Infections. Clin Infect Dis. 2016;63(12):1615\u20138.","journal-title":"Clin Infect Dis"},{"key":"350_CR9","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Press EG, Chen L, Kreiswirth BN, Clancy CJ. Emergence of ceftazidime\u2013avibactam resistance and restoration of carbapenem susceptibility in klebsiella pneumoniae carbapenemase-producing K pneumoniae: a case report and review of literature. Open Forum Infect Dis. 2017;4(3):ofx101.","DOI":"10.1093\/ofid\/ofx101"},{"key":"350_CR10","doi-asserted-by":"crossref","unstructured":"Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime\u2013avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5):e02497\u201317.","DOI":"10.1128\/AAC.02497-17"},{"key":"350_CR11","doi-asserted-by":"crossref","unstructured":"Kawai A, McElheny CL, Iovleva A, et al. Structural basis of reduced susceptibility to ceftazidime\u2013avibactam and cefiderocol in enterobacter cloacae due to AmpC R2 loop deletion. Antimicrob Agents Chemother. 2020:e00198\u201320.","DOI":"10.1128\/AAC.00198-20"},{"issue":"11","key":"350_CR12","doi-asserted-by":"publisher","first-page":"e01443","DOI":"10.1128\/AAC.01443-17","volume":"61","author":"O Lomovskaya","year":"2017","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Vaborbactam: spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(11):e01443\u2013e1517.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"350_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.4155\/fmc.09.71","volume":"1","author":"SJ Baker","year":"2009","unstructured":"Baker SJ, Ding CZ, Akama T, Zhang YK, Hernandez V, Xia Y. Therapeutic potential of boron-containing compounds. Future Med Chem. 2009;1(7):1275\u201388.","journal-title":"Future Med Chem"},{"issue":"1","key":"350_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1042\/bj2090229","volume":"209","author":"T Beesley","year":"1983","unstructured":"Beesley T, Gascoyne N, Knott-Hunziker V, et al. The inhibition of class C beta-lactamases by boronic acids. Biochem J. 1983;209(1):229\u201333.","journal-title":"Biochem J"},{"issue":"9","key":"350_CR15","doi-asserted-by":"publisher","first-page":"3682","DOI":"10.1021\/acs.jmedchem.5b00127","volume":"58","author":"SJ Hecker","year":"2015","unstructured":"Hecker SJ, Reddy KR, Totrov M, et al. Discovery of a cyclic boronic acid \u03b2-lactamase inhibitor (RPX7009) with utility vs Class A serine carbapenemases. J Med Chem. 2015;58(9):3682\u201392.","journal-title":"J Med Chem"},{"issue":"9","key":"350_CR16","doi-asserted-by":"publisher","first-page":"5454","DOI":"10.1128\/AAC.00711-16","volume":"60","author":"M Castanheira","year":"2016","unstructured":"Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the \u03b2-lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2016;60(9):5454\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"350_CR17","doi-asserted-by":"publisher","first-page":"e00567","DOI":"10.1128\/AAC.00567-17","volume":"61","author":"M Castanheira","year":"2017","unstructured":"Castanheira M, Huband MD, Mendes RE, Flamm RK. Meropenem-vaborbactam tested against contemporary gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant enterobacteriaceae. Antimicrob Agents Chemother. 2017;61(9):e00567\u2013e617.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"350_CR18","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1093\/jac\/dkt118","volume":"68","author":"DM Livermore","year":"2013","unstructured":"Livermore DM, Mushtaq S. Activity of biapenem (RPX2003) combined with the boronate \u03b2-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J Antimicrob Chemother. 2013;68(8):1825\u201331.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"350_CR19","doi-asserted-by":"crossref","first-page":"e01904","DOI":"10.1128\/AAC.01904-17","volume":"62","author":"MA Hackel","year":"2018","unstructured":"Hackel MA, Lomovskaya O, Dudley MN, Karlowsky JA, Sahm DF. In vitro activity of meropenem-vaborbactam against clinical isolates of KPC-positive Enterobacteriaceae. Antimicrob Agents Chemother. 2018;62(1):e01904\u2013e1917.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"350_CR20","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.diagmicrobio.2018.09.017","volume":"93","author":"PM Kinn","year":"2019","unstructured":"Kinn PM, Chen DJ, Gihring TM, et al. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance. Diagn Microbiol Infect Dis. 2019;93(3):258\u201360.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"350_CR21","doi-asserted-by":"publisher","first-page":"e01665","DOI":"10.1128\/AAC.01665-18","volume":"63","author":"M Sabet","year":"2018","unstructured":"Sabet M, Tarazi Z, Griffith DC. Activity of meropenem-vaborbactam against pseudomonas aeruginosa and acinetobacter baumannii in a neutropenic mouse thigh infection model. Antimicrob Agents Chemother. 2018;63(1):e01665\u2013e1718.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11\u201312","key":"350_CR22","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/23744235.2019.1653491","volume":"51","author":"E Savov","year":"2019","unstructured":"Savov E, Trifonova A, Kovachka K, Kjosseva E, Strateva T. Antimicrobial in vitro activities of ceftazidime-avibactam, meropenem-vaborbactam and plazomicin against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa\u2014a pilot Bulgarian study. Infect Dis (Lond). 2019;51(11\u201312):870\u20133.","journal-title":"Infect Dis (Lond)"},{"issue":"6","key":"350_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200868060-00006","volume":"68","author":"CM Baldwin","year":"2008","unstructured":"Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem. Drugs. 2008;68(6):803\u201338.","journal-title":"Drugs"},{"issue":"3","key":"350_CR24","doi-asserted-by":"publisher","first-page":"e0229380","DOI":"10.1371\/journal.pone.0229380","volume":"15","author":"I Lutsar","year":"2020","unstructured":"Lutsar I, Chazallon C, Trafojer U, et al. Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): a randomised controlled trial. PLoS ONE. 2020;15(3):e0229380.","journal-title":"PLoS ONE"},{"issue":"7","key":"350_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.2165\/00003495-200767070-00006","volume":"67","author":"GG Zhanel","year":"2007","unstructured":"Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs. 2007;67(7):1027\u201352.","journal-title":"Drugs"},{"key":"350_CR26","doi-asserted-by":"crossref","unstructured":"Patel TS, Kaye KS, Krishnan J, et al. 521. Comparative in vitro activity of meropenem\/vaborbactam and meropenem against a collection of real-world clinical isolates of Pseudomonas aeruginosa. Open Forum Infect Di. 2019;6(Supplement_2):S251\u2013S.","DOI":"10.1093\/ofid\/ofz360.590"},{"issue":"8","key":"350_CR27","doi-asserted-by":"publisher","first-page":"4856","DOI":"10.1128\/AAC.00843-15","volume":"59","author":"A Lapuebla","year":"2015","unstructured":"Lapuebla A, Abdallah M, Olafisoye O, et al. Activity of meropenem combined with RPX7009, a novel beta-lactamase inhibitor, against gram-negative clinical isolates in New York City. Antimicrob Agents Chemother. 2015;59(8):4856\u201360.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR28","doi-asserted-by":"crossref","unstructured":"Castanheira M, Doyle TB, Kantro V, Mendes RE, Shortridge D. Meropenem-vaborbactam activity against carbapenem-resistant enterobacterales isolates collected in U.S. Hospitals during 2016 to 2018. Antimicrob Agents Chemother. 2020;64(2):e01951\u201319.","DOI":"10.1128\/AAC.01951-19"},{"key":"350_CR29","unstructured":"CLSI. Performance Standards for Antimicrobial Susceptibility Testing. 30th ed.\u00a0 CLSI Supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute. 2020."},{"issue":"2","key":"350_CR30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ijantimicag.2018.02.021","volume":"52","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. In vitro activity of meropenem\/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem\/vaborbactam surveillance programme. Int J Antimicrob Agents. 2018;52(2):144\u201350.","journal-title":"Int J Antimicrob Agents"},{"issue":"6","key":"350_CR31","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1128\/AAC.02418-12","volume":"57","author":"EJC Goldstein","year":"2013","unstructured":"Goldstein EJC, Citron DM, Tyrrell KL, Merriam CV. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine \u03b2-lactamase inhibitor, against anaerobic bacteria. Antimicrob Agents Chemother. 2013;57(6):2620\u201330.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR32","doi-asserted-by":"crossref","unstructured":"Dulyayangkul P, Wan Nur Ismah WAK, Douglas EJA, Avison MB. Mutation of KVR causes OmpK35 and OmpK36 Porin Downregulation and reduced meropenem-vaborbactam susceptibility in KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020;64(7):e02208\u201319.","DOI":"10.1128\/AAC.02208-19"},{"issue":"3","key":"350_CR33","doi-asserted-by":"publisher","first-page":"e02048","DOI":"10.1128\/AAC.02048-18","volume":"63","author":"WR Wilson","year":"2019","unstructured":"Wilson WR, Kline EG, Jones CE, et al. Effects of KPC variant and Porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 2019;63(3):e02048\u2013e2118.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR34","doi-asserted-by":"crossref","unstructured":"Lomovskaya O, Castanheira M, Vazquez J, et al. Assessment of MIC increases with meropenem-vaborbactam and ceftazidime-avibactam in TANGO II (a Phase 3 Study of the Treatment of CRE Infections). Abstract No.1874. Open Forum Infect Dis. 2017;4(suppl_1):S540\u2013S.","DOI":"10.1093\/ofid\/ofx163.1404"},{"issue":"5","key":"350_CR35","doi-asserted-by":"publisher","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","volume":"64","author":"R Ackley","year":"2020","unstructured":"Ackley R, Roshdy D, Meredith J, et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2020;64(5):e02313\u2013e2319.","journal-title":"Antimicrob Agents Chemother"},{"key":"350_CR36","unstructured":"The Medicines Company. VABOMERE\u2122 (meropenem and vaborbactam) for injection, for intravenous use (Package Insert). 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/209776lbl.pdf. Accessed 22 Aug 2019."},{"key":"350_CR37","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters, version 10.0. 2020."}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-020-00350-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-020-00350-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T16:38:49Z","timestamp":1633451929000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-020-00350-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1007\/s40121-020-00350-1","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,5]]},"assertion":[{"value":"16 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}